Heart Failure and T2D
Two Peas in a Pod
SATURDAY, OCTOBER 3, 2020 | 1:30 PM – 2:45 PM EDT
VIRTUAL EVENT

MODERATOR
James L. Januzzi Jr, MD
Hutter Family Professor of Medicine
Division of Cardiology
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

PANELISTS
Javed Butler, MD, MBA, MPH
Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman
Department of Medicine
Professor of Physiology
University of Mississippi
Jackson, Mississippi

Mikhail Kosiborod, MD
Professor of Medicine
University of Missouri – Kansas City
School of Medicine
Saint Luke’s Mid America Heart Institute
Kansas City, Kansas

Ileana L. Piña, MD, MPH,
FAHA, FACC
Professor of Medicine
Wayne State Univ
Clinical Prof of Medicine
Central Michigan University
Detroit, Michigan

AGENDA
1:30 PM
Welcome and Introduction
James L. Januzzi Jr, MD

1:35 PM
HF and T2D: Examining the Connection
Mikhail Kosiborod, MD

1:50 PM
More Numbers That Matter: Impact of SGLT2 Inhibitors on HHF
James L. Januzzi Jr, MD

2:10 PM
On the Horizon: Upcoming Trials With SGLT2 Inhibitors
Javed Butler, MD, MBA, MPH

2:20 PM
From Benchside to Practice: Best Practices in Applying Data to Improve Management of HF in Patients With T2D
Ileana L. Piña, MD, MPH, FAHA, FACC

2:35 PM
Summary, Live Q&A
All Faculty, led by James L. Januzzi Jr, MD

2:45 PM
Adjourn

TARGET AUDIENCE
This activity is intended for heart failure specialists involved in the management of patients with heart failure (HF) and type 2 diabetes (T2D).

LEARNING OBJECTIVES
Upon completion of this activity, participants will:

• Have increased knowledge regarding the
  • Relationship between T2D and HF
  • New data demonstrating benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors on hospitalizations for HF (HHF) and other HF-related outcomes
  • Comparison of HF-related cardiovascular outcomes trial (CVOT) data for SGLT2 inhibitors
  • Trial designs of ongoing outcomes trials examining SGLT2 inhibitors as treatment for both acute and chronic HF

• Have greater competence related to
  • Application of new data and guidelines to management of patients with T2D and HF

ACCREDITATION STATEMENT
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

THIS SATELLITE SYMPOSIUM IS NOT PART OF THE SCIENTIFIC PROGRAM AS PLANNED BY THE HEART FAILURE SOCIETY OF AMERICA PROGRAM COMMITTEE.

Supported by an independent educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc., and Lilly USA, LLC.

ELIGIBILITY: Registration for the HFSA Virtual Annual Scientific Meeting is required to attend this symposium.